Core Viewpoint - Meirui Health International (02327) expects a significant increase in shareholder profit for the six months ending June 30, 2025, projected between approximately HKD 14 million to HKD 16 million, compared to approximately HKD 8.2 million for the same period ending June 30, 2024 [1] Group 1: Profit Expectations - The anticipated increase in profit is primarily due to growth in property-related business revenue and profit, driven by increased rental income and stable fair value of investment properties for the six months ending June 30, 2025, in contrast to a significant decline in fair value for the same period in 2024 [1] - Interest income has risen as the company effectively utilized idle funds to provide short-term interest-bearing loans and long-term revolving financing to clients and related parties [1] Group 2: Challenges - The domestic operating environment remains challenging, leading to a decrease in trade sales and revenue from health and medical-related products [1]

Core Viewpoint - Mei Rui Health International (02327) expects to achieve a profit attributable to shareholders between approximately HKD 14 million and HKD 16 million for the six months ending June 30, 2025, compared to approximately HKD 8.2 million for the six months ending June 30, 2024 [1] Group 1: Profit Expectations - The anticipated increase in profit is primarily due to growth in property-related business revenue and profit, driven by increased rental income and stable fair value of investment properties for the six months ending June 30, 2025 [1] - In contrast, the fair value of investment properties experienced a significant decline for the six months ending June 30, 2024 [1] Group 2: Interest Income - The company benefited from effectively utilizing idle funds to provide short-term interest-bearing loans and long-term revolving financing to clients and related parties, resulting in increased interest income [1] Group 3: Adverse Factors - These positive factors were partially offset by a challenging domestic operating environment, leading to a decrease in trade sales and revenue from health and medical-related products [1]

Core Viewpoint - Meirui Health International (02327.HK) expects a significant increase in shareholder profit for the six months ending June 30, 2025, projecting between approximately HKD 14 million to HKD 16 million, compared to approximately HKD 8.2 million for the six months ending June 30, 2024 [1] Group 1: Profit Expectations - The anticipated increase in profit is primarily due to growth in property-related business revenue and profit, driven by increased rental income and stable fair value of investment properties [1] - The fair value of investment properties experienced a significant decline for the six months ending June 30, 2024, contrasting with the stability expected for the upcoming period [1] Group 2: Revenue Sources - The company has benefited from utilizing idle funds to provide short-term interest-bearing loans and long-term revolving financing to clients and related parties, resulting in increased interest income [1] - However, this positive impact is partially offset by a challenging domestic operating environment, leading to a decrease in trade sales and revenue from health and medical-related products [1]